Clinical trials in recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 771-775

  Friedlander, Michael ^a   Trimble, Edward ^b   Tinker, Anna ^a   Alberts, David ^a   Avall Lundqvist, Elisabeth ^a   Brady, Mark ^a   Harter, Philipp ^a   Pignata, Sandro ^a   Pujade Lauraine, Eric ^a   Sehouli, Jalid ^a   Vergote, Ignace ^a   Beale, Philip ^a   Bekkers, Rudd ^a   Calvert, Paula ^a   Copeland, Lawrence ^a   Glasspool, Ros ^a   Gonzalez Martin, Antonio ^a   Katsaros, Dionysis ^a   Kim, Jae Won ^a   Miller, Brigitte ^a   Provencher, Diane ^a   Rubinstein, Lawrence ^b   Atri, Mostafa ^a   Zeimet, Alain ^a   Bacon, Monica ^a   Kitchener, Henry ^c   Stuart, Gavin C E ^a   more..

^a ANZGOG ^*  (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Clinical trials; Ovarian cancer; Recurrent

Indexed keywords

CA 125 ANTIGEN;

CANCER GROWTH; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; HUMAN; OVARY CANCER; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL;

CARCINOMA; CLINICAL TRIALS AS TOPIC; CONSENSUS; ENDPOINT DETERMINATION; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; RECURRENCE;

EID: 80051910971     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821bb8aa     Document Type: Conference Paper

References (22)

1. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:256-274.
2. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324-1330.
3. Harter P, Hilpert F, Mahner S, et al. Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer. 2009;19:S14-S17.
4. Funicelli L, Travaini LL, Landoni F, et al. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [(18)FDG-PET/CT. Abdom Imaging. 2010;35:701-707.
5. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT, and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164-174.
6. Sala E, Katakoka M, Pandi-Taskar N, et al. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival. Radiology. 2010;257:125-134.
7. Kim CK, Park BK, Choi JY, et al. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr. 2007;31:868-875. (Pubitemid 350196929)
8. Klostergaard J, Parga K, Raptis RG. Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management. P R Health Sci J. 2010;29:223-231.
9. Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010;20:936-944.
10. Blackledge G, Lawton F, REdman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59:650-653. (Pubitemid 19111764)
11. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207-211. (Pubitemid 20061287)
12. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
13. Goonewardene TI, Hall MR, Rusting GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821 (Pubitemid 47308670)
14. ten Bokkel Huinik W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193. (Pubitemid 27251118)
15. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AVAR-2.2 Trial. Lancet. 2003;361:2099-2106.
16. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707. (Pubitemid 46630933)
17. Rustin GJS, van der Berg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
18. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovarian Group Study. Ann Oncol. 1996;7:361-364. (Pubitemid 26246787)
19. Rustin GJ, Marples M, Nelstrong AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057. (Pubitemid 32976692)
20. Rustin GJS, Quinn M, Thigpen T, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96:487-488. (Pubitemid 38443654)
21. Burger RA, Brady MF, Bookman, MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract]. J Clin Oncol. 2010;28:LBA1.
22. Perren T, Swart AM, Pfisterer J, et al. ICON7: phase III randomized Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract]. Ann Oncol. 2010;:viii2-viii3. LBA4.